New Zealand's MoleMap technology will be used at a leading American hospital to advance skin cancer research and help to find new ways to detect melanoma earlier.
MoleMap chief executive Adrian Bowling said today that New York University had decided to establish a MoleMap clinic within its hospital, the Langone Medical Centre.
The centre's Charles C Harris Skin and Cancer Unit had adopted the Molemap software and database and its researcher would have access to thousands of New Zealand and Australian melanoma case studies.
MoleMap, known as Molesafe in the United States, was established in New Zealand in 1998 by a group of dermatologists.
It is described as the world's most advanced melanoma detection programme.
Elsewhere in New York, the Memorial Sloan-Kettering Cancer Centre is using the MoleMap database for its research into pigmented moles.
Mr Bowling said NYU's decision showed the value of the technology as a diagnostic tool.
US News and World Report last year included the Langone Medical Centre among 21 hospitals it rated as "America's Best".
NZPA